A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia - PubMe
2 hours ago
- #Continuous Subcutaneous Insulin Infusion
- #Type 2 Diabetes Mellitus
- #Henagliflozin
- Study evaluates henagliflozin plus continuous subcutaneous insulin infusion (CSII) for type 2 diabetes mellitus (T2DM) patients with severe hyperglycaemia.
- 210 adults with T2DM were randomly assigned to either henagliflozin+CSII or CSII alone for 7 days.
- Primary endpoint: time in range (TIR) of 3.9-10.0 mmol/L blood glucose.
- Henagliflozin+CSII showed significantly greater TIR (79.85% vs. 74.06%) and faster target glucose achievement than CSII alone.
- Henagliflozin+CSII group had lower time above range (TAR), insulin dosage, mean glucose (MG), and glucose management indicator (GMI).
- No significant differences in adverse events (e.g., urinary tract infection, hypoglycaemia) between groups.
- Conclusion: Henagliflozin+CSII improves glycaemic control and reduces insulin needs with comparable safety to CSII alone.